Literature DB >> 24061861

Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer.

Pilar Garre1, Lorena Martín, Inmaculada Bando, Alicia Tosar, Patricia Llovet, Julián Sanz, Atocha Romero, Miguel de la Hoya, Eduardo Díaz-Rubio, Trinidad Caldés.   

Abstract

Mismatch repair proficient hereditary non-polyposis colorectal cancer (MSS-HNPCC) encloses a heterogeneous group of families consisting of different unknown genetic syndromes and/or aggregations cases. The lack of information about the hereditability of cancer risk in these families makes it difficult to carry out an individualized Genetic Counseling. Therefore, deep description of such families becomes important for a better classification and search for underlying susceptibility causes. The aim of this study is to describe and compare the clinical, morphological features, tumor KRAS status and overall survival in MSS-HNPCC, Lynch and sporadic colorectal cancer. A total of 37 MSS-HNPCC families, 50 Lynch families and 612 sporadic CRC were included. Clinical and morphological data were evaluated by reviewing medical and pathology reports of 55, 69 and 102 tumors respectively. KRAS/BRAF status were detected by allele specific real-time PCR. Standardized incidence ratios (SIR) were calculated among 602 MSS-HNPCC relatives and 668 Lynch relatives. Main features distinguishing MSS-HNPCC were diagnosis age (55.1 ± 12.6), preferential distal location (76%), polyp detection (45%) and familial colorectal cancer incidence (SIR = 6.6). In addition, we found increased incidences rates for kidney, stomach and uterus tumors. KRAS mutation rates were similar in the study populations (48.8 ± 5.8) but higher than those described before by Sanger sequencing. MSS-HNPCC overall survival was similar to Lynch in B Dukes' stage tumors and between Lynch and sporadic in C stage tumors. Anatomical and morphological data of MSS-HNPCC are consistent with other described populations. Our studies disclose an increased HNPCC-extracolonic tumors incidence and improved overall survival in MSS-HNPCC families.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24061861     DOI: 10.1007/s10689-013-9683-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  50 in total

1.  Denaturing gradient gel electrophoresis-based analysis of loss of heterozygosity distinguishes nonobvious, deleterious BRCA1 variants from nonpathogenic polymorphisms.

Authors:  M de La Hoya; E Díaz-Rubio; T Caldés
Journal:  Clin Chem       Date:  1999-11       Impact factor: 8.327

2.  Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status.

Authors:  Laura Valle; Jose Perea; Pablo Carbonell; Victoria Fernandez; Ana M Dotor; Javier Benitez; Miguel Urioste
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

3.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

4.  Low prevalence of germline hMSH6 mutations in colorectal cancer families from Spain.

Authors:  Ana Sánchez de Abajo; Miguel de la Hoya; Alicia Tosar; Javier Godino; Juan-Manuel Fernández; Jose-Lopez Asenjo; Beatriz-Perez Villamil; Pedro-Perez Segura; Eduardo Diaz-Rubio; Trinidad Caldes
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

5.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Authors:  Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

6.  Analysis of the oxidative damage repair genes NUDT1, OGG1, and MUTYH in patients from mismatch repair proficient HNPCC families (MSS-HNPCC).

Authors:  Pilar Garre; Verónica Briceño; Rosa M Xicola; Brian J Doyle; Miguel de la Hoya; Julián Sanz; Patricia Llovet; Paula Pescador; Javier Puente; Eduardo Díaz-Rubio; Xavier Llor; Trinidad Caldés
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

7.  Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations.

Authors:  Wael M Abdel-Rahman; Miina Ollikainen; Reetta Kariola; Heikki J Järvinen; Jukka-Pekka Mecklin; Minna Nyström-Lahti; Sakari Knuutila; Päivi Peltomäki
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

8.  Study of KRAS new predictive marker in a clinical laboratory.

Authors:  Inmaculada Bando; Lourdes Cillero; Julián Sanz-Ortega; Patricia Llovet; Paula Pescador; Milagros Ferrer; Miguel de la Hoya; Javier Sastre; Eduardo Díaz-Rubio García; Trinidad Caldés
Journal:  Clin Transl Oncol       Date:  2012-08-03       Impact factor: 3.405

9.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

10.  A pyrosequencing-tailored nucleotide barcode design unveils opportunities for large-scale sample multiplexing.

Authors:  Poornima Parameswaran; Roxana Jalili; Li Tao; Shadi Shokralla; Baback Gharizadeh; Mostafa Ronaghi; Andrew Z Fire
Journal:  Nucleic Acids Res       Date:  2007-10-11       Impact factor: 16.971

View more
  5 in total

Review 1.  Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge.

Authors:  Henry T Lynch; Stephen Lanspa; Trudy Shaw; Murray Joseph Casey; Marc Rendell; Mark Stacey; Theresa Townley; Carrie Snyder; Megan Hitchins; Joan Bailey-Wilson
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

2.  Immunohistochemical expression pattern of MMR protein can specifically identify patients with colorectal cancer microsatellite instability.

Authors:  Arfaoui Toumi Amira; Trabelsi Mouna; Blel Ahlem; Aloui Raoudha; Ben Hmida Majid; Hamza Amel; Zermani Rachida; Kourdaa Nadia
Journal:  Tumour Biol       Date:  2014-03-19

3.  Hereditary colorectal cancer syndromes and the COVID-19 pandemic: results from a survey conducted in patients enrolled in a dedicated registry.

Authors:  Stefano Signoroni; Chiara Maura Ciniselli; Giovanni Apolone; Marco Vitellaro; Guglielmo Niccolò Piozzi; Maria Teresa Ricci; Marta Pastori; Paolo Merola; Marco Bellazzi; Tatiana Smaldone; Giuseppe Rosito; Claudia Borreani; Paolo Verderio
Journal:  Qual Life Res       Date:  2021-08-23       Impact factor: 3.440

4.  Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.

Authors:  Wenbin Li; Wenxue Zhi; Shuangmei Zou; Tian Qiu; Yun Ling; Ling Shan; Susheng Shi; Jianming Ying
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

5.  Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition.

Authors:  Lorena Martin-Morales; Paula Rofes; Eduardo Diaz-Rubio; Patricia Llovet; Victor Lorca; Inmaculada Bando; Pedro Perez-Segura; Miguel de la Hoya; Pilar Garre; Vanesa Garcia-Barberan; Trinidad Caldes
Journal:  PLoS One       Date:  2018-09-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.